Literature DB >> 15148255

Piracetam and TRH analogues antagonise inhibition by barbiturates, diazepam, melatonin and galanin of human erythrocyte D-glucose transport.

Richard J Naftalin1, Philip Cunningham, Iram Afzal-Ahmed.   

Abstract

1 Nootropic drugs increase glucose uptake into anaesthetised brain and into Alzheimer's diseased brain. Thyrotropin-releasing hormone, TRH, which has a chemical structure similar to nootropics increases cerebellar uptake of glucose in murine rolling ataxia. This paper shows that nootropic drugs like piracetam (2-oxo 1 pyrrolidine acetamide) and levetiracetam and neuropeptides like TRH antagonise the inhibition of glucose transport by barbiturates, diazepam, melatonin and endogenous neuropeptide galanin in human erythrocytes in vitro. 2 The potencies of nootropic drugs in opposing scopolamine-induced memory loss correlate with their potencies in antagonising pentobarbital inhibition of erythrocyte glucose transport in vitro (P<0.01). Less potent nootropics, D-levetiracetam and D-pyroglutamate, have higher antagonist Ki's against pentobarbital inhibition of glucose transport than more potent L-stereoisomers (P<0.001). 3 Piracetam and TRH have no direct effects on net glucose transport, but competitively antagonise hypnotic drug inhibition of glucose transport. Other nootropics, like aniracetam and levetiracetam, while antagonising pentobarbital action, also inhibit glucose transport. Analeptics like bemigride and methamphetamine are more potent inhibitors of glucose transport than antagonists of hypnotic action on glucose transport. 4 There are similarities between amino-acid sequences in human glucose transport protein isoform 1 (GLUT1) and the benzodiazepine-binding domains of GABAA (gamma amino butyric acid) receptor subunits. Mapped on a 3D template of GLUT1, these homologies suggest that the site of diazepam and piracetam interaction is a pocket outside the central hydrophilic pore region. 5 Nootropic pyrrolidone antagonism of hypnotic drug inhibition of glucose transport in vitro may be an analogue of TRH antagonism of galanin-induced narcosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15148255      PMCID: PMC1574967          DOI: 10.1038/sj.bjp.0705798

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  95 in total

1.  Sequence and structure of a human glucose transporter.

Authors:  M Mueckler; C Caruso; S A Baldwin; M Panico; I Blench; H R Morris; W J Allard; G E Lienhard; H F Lodish
Journal:  Science       Date:  1985-09-06       Impact factor: 47.728

2.  [Interaction of piracetam with 3H-imipramine binding sites and the GAMA-benzodiazepine receptor complex of brain membranes].

Authors:  V V Rozhanets; K K Chakhbra; N D Danchev; K M Malin; D Iu Rusakov
Journal:  Biull Eksp Biol Med       Date:  1986-01

3.  Intravenous thyrotropin-releasing hormone in patients with amyotrophic lateral sclerosis. Dose-response and randomized concurrent placebo-controlled pilot studies.

Authors:  B R Brooks; R L Sufit; G K Montgomery; D A Beaulieu; L M Erickson
Journal:  Neurol Clin       Date:  1987-02       Impact factor: 3.806

4.  The effect of diazepam upon local cerebral glucose use in the conscious rat.

Authors:  P A Kelly; I Ford; J McCulloch
Journal:  Neuroscience       Date:  1986-09       Impact factor: 3.590

5.  [Multicomponent antithrombotic effect of the neuroprotective prolyl dipeptide GVS-111 and its major metabolite cyclo-L-prolylglycine].

Authors:  R U Ostrovskaia; L A Liapina; V E Pastorova; T Kh Mirzoev; T A Gudasheva; S B Seredenin; I P Ashmarin
Journal:  Eksp Klin Farmakol       Date:  2002 Mar-Apr

6.  DM235 (sunifiram): a novel nootropic with potential as a cognitive enhancer.

Authors:  C Ghelardini; N Galeotti; F Gualtieri; M N Romanelli; C Bucherelli; E Baldi; A Bartolini
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2002-05-15       Impact factor: 3.000

7.  Comparison of PET, MRI, and CT with pathology in a proven case of Alzheimer's disease.

Authors:  P L McGeer; H Kamo; R Harrop; E G McGeer; W R Martin; B D Pate; D K Li
Journal:  Neurology       Date:  1986-12       Impact factor: 9.910

8.  The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents.

Authors:  J-M Rigo; G Hans; L Nguyen; V Rocher; S Belachew; B Malgrange; P Leprince; G Moonen; I Selak; A Matagne; H Klitgaard
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

9.  Role of TRH receptors as possible mediators of analeptic actions of TRH-like peptides.

Authors:  Patricia M Hinkle; A Eugene Pekary; Shayani Senanayaki; Albert Sattin
Journal:  Brain Res       Date:  2002-05-10       Impact factor: 3.252

Review 10.  Anxiety over GABA(A) receptor structure relieved by AChBP.

Authors:  Brett A Cromer; Craig J Morton; Michael W Parker
Journal:  Trends Biochem Sci       Date:  2002-06       Impact factor: 13.807

View more
  3 in total

1.  The metabolic enhancer piracetam ameliorates the impairment of mitochondrial function and neurite outgrowth induced by beta-amyloid peptide.

Authors:  C Kurz; I Ungerer; U Lipka; S Kirr; T Schütt; A Eckert; K Leuner; W E Müller
Journal:  Br J Pharmacol       Date:  2010-03-09       Impact factor: 8.739

2.  Piracetam improves mitochondrial dysfunction following oxidative stress.

Authors:  Uta Keil; Isabel Scherping; Susanne Hauptmann; Katin Schuessel; Anne Eckert; Walter E Müller
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 3.  Mitochondrial dysfunction: common final pathway in brain aging and Alzheimer's disease--therapeutic aspects.

Authors:  Walter E Müller; Anne Eckert; Christopher Kurz; Gunter Peter Eckert; Kristina Leuner
Journal:  Mol Neurobiol       Date:  2010-05-12       Impact factor: 5.590

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.